It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Neurodegeneration is the primary driver of disease progression in multiple sclerosis (MS) resulting in permanent disability, creating an urgent need to discover its underlying mechanisms. Herein, we establish that dysfunction of the RNA binding protein heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) results in differential of binding to RNA targets causing alternative RNA splicing, which contributes to neurodegeneration in MS and its models. Using RNAseq of MS brains, we discovered differential expression and aberrant splicing of hnRNP A1 target RNAs involved in neuronal function and RNA homeostasis. We confirmed this in vivo in experimental autoimmune encephalomyelitis employing CLIPseq specific for hnRNP A1, where hnRNP A1 differentially binds and regulates RNA, including aberrantly spliced targets identified in human samples. Additionally, dysfunctional hnRNP A1 expression in neurons caused neurite loss and identical changes in splicing, corroborating hnRNP A1 dysfunction as a cause of neurodegeneration. Collectively, these data indicate hnRNP A1 dysfunction causes altered neuronal RNA splicing, resulting in neurodegeneration in MS.
HnRNP A1 dysfunction is associated with neurodegeneration in multiple sclerosis (MS). Herein, advanced RNA sequencing and CLIPseq of MS brains and relevant models demonstrated that hnRNP A1 binding of target RNAs and RNA splicing were altered, precipitating neurodegeneration.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 University of Saskatchewan, Office of the Saskatchewan Multiple Sclerosis Clinical Research Chair, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X); University of Saskatchewan, Cameco MS Neuroscience Research Centre, College of Medicine, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X); University of Saskatchewan, Neurology Division, Department of Medicine, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)
2 University of Saskatchewan, Office of the Saskatchewan Multiple Sclerosis Clinical Research Chair, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X); University of Saskatchewan, Cameco MS Neuroscience Research Centre, College of Medicine, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X); University of Saskatchewan, Department of Health Sciences, College of Medicine, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)
3 University of Saskatchewan, Division of Oncology, College of Medicine, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X); University of Saskatchewan, Division of Biomedical Engineering, College of Medicine, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)
4 University of Saskatchewan, Division of Oncology, College of Medicine, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)
5 University of Saskatchewan, Office of the Saskatchewan Multiple Sclerosis Clinical Research Chair, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X); University of Saskatchewan, Cameco MS Neuroscience Research Centre, College of Medicine, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X); University of Saskatchewan, Department of Anatomy, Physiology and Pharmacology, College of Medicine, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)
6 University of Saskatchewan, Next-Generation Sequencing Facility, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)
7 University of Saskatchewan, Advanced Diagnostics Research Laboratory, Department of Pathology and Lab Medicine, College of Medicine, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)
8 University of Saskatchewan, Department of Pathology and Laboratory Medicine, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)
9 University of Saskatchewan, Office of the Saskatchewan Multiple Sclerosis Clinical Research Chair, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X); University of Saskatchewan, Cameco MS Neuroscience Research Centre, College of Medicine, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X); University of Saskatchewan, Neurology Division, Department of Medicine, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X); University of Saskatchewan, Department of Anatomy, Physiology and Pharmacology, College of Medicine, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)